Running Head: PRIMERO Birth Cohort

1 Word counts

- 2 Text: 3,980
- 3 Abstract: 200
- 4

5 Title: The Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes

- 6 (PRIMERO): Design and Baseline Characteristics for a Birth Cohort Study of Early-life Viral
- 7 Respiratory Illnesses and Airway Dysfunction in Puerto Rican Children
- 8 Running head: PRIMERO Cohort
- **9** Author list: Jonathan I. Witonsky^{*}, MD, MAS; Jennifer R. Elhawary^{*}, MS; Celeste Eng, BS;
- 10 Sam S. Oh, PhD, MPH; Sandra Salazar; Maria G. Contreras, BS; Vivian Medina, RN, BSN, SC;
- 11 Elizabeth A. Secor, MA; Priscilla Zhang, BS; Jamie L. Everman, PhD; Ana Fairbanks-Mahnke,
- 12 BS; Elmar Pruesse, PhD; Satria P. Sajuthi, PhD; Chih-Hao Chang, PhD, MPH; Tsunami Rosado
- 13 Guerrero, BS; Keyshla Canales Fuentes, BS; Natalie Lopez, MD; Chris Angely Montanez-
- 14 Lopez, BS; Richeliz Alfonso Otero, MD; Raymarie Colon Rivera, BS; Leysha Rodriguez, BA;
- 15 Gabriela Vazquez, BS; Donglei Hu, PhD; Scott Huntsman, MS; Nathan D. Jackson, PhD;
- 16 Yingchun Li, MD, PhD; Andrew Morin, MA; Natalie A. Nieves, BS; Cydney Rios, BS; Gonzalo
- 17 Serrano, BS; Blake J. M. Williams, MS; Elad Ziv, MD; Camille M. Moore, PhD; Dean
- 18 Sheppard, MD; Esteban Gonzalez Burchard[#], MD, MPH; Max A. Seibold[#], PhD; and Jose R.
- 19 Rodriguez Santana[#], MD
- 20 ^{*}Shared first authorship
- 21 [#]Shared senior authorship

22 Affiliations: From the Department of Pediatrics (Dr Witonsky) and Department of Medicine (Ms

- 23 Elhawary, Ms Eng, Dr Oh, Ms Salazar, Ms Contreras, Ms Zhang, Dr Chang, Dr Hu, Mr
- 24 Huntsman, Dr Ziv, Dr Sheppard, and Dr Burchard), University of California, San Francisco, San
- 25 Francisco, CA; Centro de Neumología Pediátrica (Ms Medina, Ms Fuentes, Ms Guerrero, Dr

Running Head: PRIMERO Birth Cohort

26	Lopez, Ms Montanez-Lopez, Dr Otero, Ms Rivera, Ms Rodriguez, Ms Vazquez, Ms Nieves, Ms
27	Serrano, and Dr Rodríguez Santana), San Juan, PR; Center for Genes, Environment & Health
28	(Ms Secor, Dr Everman, Ms Fairbanks-Mahnke, Dr Pruesse, Dr Sajuthi, Dr Jackson, Dr Li, Mr
29	Morin, Ms Rios, Mr Williams, Dr Moore, and Dr Seibold), National Jewish Health, Denver, CO;
30	and the Department of Pediatrics and Division of Pulmonary Sciences and Critical Care
31	Medicine, Department of Medicine (Dr. Seibold), University of Colorado, Aurora, CO.
32	
33	Correspondence to: Jonathan Witonsky, MD, MAS, Department of Pediatrics, University of
34	California, San Francisco, 550 16th Street, 4th Floor, San Francisco, CA, 94143; e-mail:
35	jonathan.witonsky@ucsf.edu

36

Funding information:

This work was supported in part by the Sandler Family Foundation; the American Asthma 38 39 Foundation; the RWJF Amos Medical Faculty Development Program; Harry Wm. and Diana V. 40 Hind Distinguished Professor in Pharmaceutical Sciences II; the American Lung Association 41 [CAALA2023]; Wohlberg and Lambert Endowed Chair of Pharmacogenomics (MAS); 42 the National Institutes of Health, National Heart, Lung, and Blood Institute [5U01HL138626 and 43 1K23HL169911]. The content of this publication is solely the responsibility of the authors and 44 does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply 45 endorsement by the U.S. government. 46

Running Head: PRIMERO Birth Cohort

47 Abstract

Epidemiologic studies demonstrate an association between early-life respiratory illnesses (RIs) 48 49 and the development of childhood asthma. However, it remains uncertain whether these children 50 are predisposed to both conditions or if early-life RIs induce alterations in airway function. 51 immune responses, or other human biology that contribute to the development of asthma. Puerto 52 Rican children experience a disproportionate burden of early-life RIs and asthma, making them 53 an important population for investigating this complex interplay. PRIMERO, the Puerto Rican Infant Metagenomics and Epidemiologic Study of Respiratory Outcomes, recruited pregnant 54 women and their newborns to investigate how the airways develop in early life among infants 55 56 exposed to different viral RIs, and will thus provide a critical understanding of childhood asthma 57 development. As the first asthma birth cohort in Puerto Rico, PRIMERO will prospectively 58 follow 2,100 term healthy infants. Collected samples include post-term maternal peripheral 59 blood, infant cord blood, the child's peripheral blood at the year two visit, and the child's nasal airway epithelium, collected using minimally invasive nasal swabs, at birth, during RIs over the 60 61 first two years of life, and at annual healthy visits until age five. Herein, we describe the study's 62 design, population, recruitment strategy, study visits and procedures, and primary outcomes.

Running Head: PRIMERO Birth Cohort

63 INTRODUCTION

64 Asthma is the most common chronic condition in childhood, disproportionately affecting children from racially and ethnically minoritized backgrounds (1). Asthma is over 40% more 65 66 prevalent among Black and Latino children compared to their non-Hispanic white counterparts, 67 and Puerto Rican children face a threefold higher likelihood of having asthma and an over fivefold higher risk of asthma-related mortality (2-4). The development of asthma is influenced 68 69 by complex gene-by-environment interactions that remain poorly understood (5-13). It is 70 hypothesized that a key factor perpetuating asthma inequities among Puerto Rican children is their increased early-life exposure to environmental risk factors, particularly to asthma-genic 71 72 respiratory viral pathogens, which are both ubiquitous and endemic in Puerto Rico (13–16). 73 Irrespective of race or ethnicity, viral infections causing lower respiratory tract symptoms in the 74 first two years of life are commonly linked to the subsequent development of recurrent wheezing 75 and childhood asthma (17,18). In particular, infants who had bronchiolitis or wheezing induced 76 by respiratory syncytial virus (RSV) face a 2.6-fold increased likelihood of developing asthma at 77 six years of age (14). Furthermore, a recent prospective study found that children who remained 78 free from RSV infection by one year of age had a 26% lower risk of developing asthma before age five than those infected with RSV by the same age (19). Similarly, children with early-life 79 80 wheezing illnesses caused by human rhinoviruses (HRV) face a 9.8-fold increased risk of 81 developing asthma at age six years (14).

82

Despite these findings, more studies are needed to examine the asthma risk attributable to earlylife illnesses caused by RSV versus HRV, as well as the risk associated with other common
respiratory viruses infecting young children. Additionally, the causative mechanisms underlying

86	these associations still need to be determined. One plausible explanation is that infections with
87	these respiratory viruses induce epithelial barrier dysfunction that leads to the development of
88	asthma (20–25). Conversely, children may be born with specific airway or immune defects
89	predisposing them to both poor responses to viral infections and an increased likelihood of
90	developing asthma (26). If the former holds, mitigating lower respiratory tract illnesses (LRIs)
91	could emerge as an effective strategy for preventing the onset of asthma. Supporting this notion,
92	intervention trials focused on reducing early-life RSV infections have demonstrated efficacy in
93	preventing asthma (27). This prospect has fueled the recent development of an RSV vaccine
94	administered during pregnancy and an RSV antibody treatment for infants born during RSV
95	season to block early-life acute RSV infections and inhibit asthma development (28,29).
96	
97	The Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes, or
98	PRIMERO, is a prospective observational birth cohort study of Puerto Rican children established
99	to investigate the prevalence and role of all common respiratory viruses on the development of
100	LRIs and asthma. Specifically, PRIMERO seeks to ascertain whether the association between
101	early-life viral illness and asthma is rooted in deficiencies in the airway at birth or the subsequent
102	alterations of the airway and airway mucosal immune system in response to viral infections. To
103	achieve this aim, PRIMERO is designed to examine the molecular development and
104	pathobiology of the airway at birth and throughout early childhood, all while performing
105	surveillance for early-life respiratory illnesses, with viral and molecular response
106	characterization of the detected illnesses. In contrast to prior birth cohort studies, our study
107	utilizes cutting-edge multiplexed molecular assays, which allow us to identify illnesses caused
108	by both RSV and HRV, in addition to metapneumovirus, coronaviruses, parainfluenza, influenza,

Running Head: PRIMERO Birth Cohort

109 and other species that have been less studied in this context. Furthermore, leveraging Puerto 110 Rican's rich genetic admixture, PRIMERO children will be genetically characterized to determine if the effects of these viruses on LRI and asthma risk are dependent on genetic 111 112 variation. Perhaps most innovative, the PRIMERO study will characterize molecular airway 113 dysfunction repeatedly at birth, yearly throughout childhood, and during respiratory illnesses, 114 through transcriptomic analyses of nasal airway mucosa, collected by swabbing the inferior nasal 115 turbinate. Importantly, our prior work in young children has shown this minimally invasive 116 technique collects both epithelia and airway immune cells, and that the cell types and expression profiles of these upper airway samples mirror those in the lower (bronchial) airways in health 117 and asthma disease (30). Leveraging this rich dataset, our goals are fourfold: [1] identify the 118 119 genetic and viral determinants of early-life LRIs, [2] elucidate the influence of LRIs caused by 120 different viral species on the development of asthma, [3] delineate the trajectories of airway 121 molecular and cellular development from birth through childhood in both children who do and 122 do not develop asthma, and [4] ascertain whether the airway developmental trajectories leading 123 to asthma are predetermined at birth or influenced by early-life viral LRIs. Beyond these goals, 124 PRIMERO's unique and comprehensive characterization of respiratory illnesses and airway 125 pathobiology during childhood offers unprecedented opportunities for further investigation into 126 the impact of prenatal and postnatal social, environmental, and genetic determinants of childhood 127 health and disease.

128

PRIMERO, a National Heart, Lung, and Blood Institute (NHLBI) funded longitudinal birth
cohort consisting of 2,100 term healthy infants, is the result of a collaborative effort among
research groups from the University of California, San Francisco (UCSF), National Jewish

Running Head: PRIMERO Birth Cohort

132	Health (NJH) in Denver, CO, and Centro de Neumología Pediátrica (CNP) in Caguas, Puerto
-----	---

133 Rico. The study meticulously tracks this cohort from birth through early childhood, incorporating

134 RI surveillance during the initial two years of life and annual airway sampling during healthy

135 child study visits. Herein, we provide a comprehensive overview of the objectives, study design,

- 136 procedures, specimen collections, and recruitment results.
- 137

138 METHODS

139 **Primary Hypotheses**

140 RIs caused by some viral species will independently increase the risk of acute lower respiratory

141 tract symptoms and asthma, while the effect of other species on these outcomes will be

dependent on host factors, including genetics. Early-life viral LRIs will directly contribute to the

risk of childhood asthma by modulating the early-life development of the airway epithelium and

immune system.

145

146 **Primary Objectives**

147 To address our hypotheses, PRIMERO pursues the following seven study objectives:

148 1. Identify the genetic and viral determinants of early-life upper RIs (URIs) and LRIs.

149 2. Determine the association between early-life RIs attributed to various viral species and both

the modified asthma predictive index (mAPI) and asthma disease in childhood.

151 3. Determine whether the risk of asthma conferred by different viral RIs is dependent on host152 factors, including genetics.

153 4. Identify distinct early-life airway gene expression patterns and cellular developmental

trajectories that contribute to asthma in childhood.

Running Head: PRIMERO Birth Cohort

155	5. Determine whether early-life viral LRIs alter airway developmental trajectories.
156	6. Determine whether the molecular and cellular profiles of the airway at birth are associated
157	with the occurrence of early-life viral LRIs and/or the development of asthma in childhood.
158	7. Determine whether the gene expression responses to viral LRIs are associated with the
159	subsequent development of asthma.
160	
161	Study Overview
162	To address these objectives, we designed PRIMERO as a prospective observational birth cohort
163	study, enrolling newborns and their mothers from March 2020 to June 2023. Surveillance for RIs
164	during the child's first two years involves weekly short message service (SMS) texts and email
165	messages, complemented by in-person visits and biospecimen collections specifically designated
166	for RIs. In addition, newborn and annual follow-up visits for the child's first five years of life are
167	used to assess respiratory health, environmental and social exposures, measure lung function,
168	and to collect biospecimens. The minimum duration of participant follow-up will be two years
169	with the aim to follow participants for a maximum of 10 years pending ongoing support of the
170	study.
171	

171

172 Established Community Engagement

PRIMERO builds upon our extensive community engagement with the Puerto Rican community,
which commenced in 1998 with the initiation of the Genetics of Asthma in Latino Americans
(GALA) Study (31). This endeavor was designed to explore the heightened rates of asthma
prevalence and morbidity among Puerto Rican children. Expanding on this groundwork, our
research progressed with the Genes-environments & Admixture in Latino Americans (GALA II

Running Head: PRIMERO Birth Cohort

178	study) spanning from 2008 to 2014 (32). This case-control study focused on asthma in Latino
179	children, including Puerto Rican participants in our recruitment, epidemiological, and genetic
180	analyses. Our efforts in GALA and GALA II resulted in over an 85% recruitment rate and a
181	follow-up contact rate exceeding 90% among Puerto Rican study participants, with GALA II
182	providing much of the preliminary data for PRIMERO.
183	
184	Study Population and Recruitment
185	PRIMERO recruited pregnant women who were receiving obstetric/gynecologic (OB/GYN)
186	services and giving birth at Hospital Interamericano de Medicina Avanzada-San Pablo (HIMA).
187	HIMA is located in Caguas, Puerto Rico, which neighbors San Juan, Puerto Rico's capital and
188	most populous municipality (Figure 1). Most babies born at HIMA (>95%) come from families
189	residing in the San Juan-Bayamón-Caguas metropolitan area, home to 63% of Puerto Rico's
190	population. Demographically, the San Juan-Bayamón-Caguas metropolitan area is similar to the
191	entire island in terms of age, marital status, birth rate, and educational attainment (33).
192	

193 Healthcare providers from HIMA's OB/GYN services were introduced to PRIMERO via 194 presentations and information sessions. Medical staff were invited to join recruitment efforts, and 195 collaborating offices received PRIMERO brochures for distribution during routine prenatal 196 visits. Women receiving information packets had their details recorded in the custom electronic 197 database, PRIMERO-DB (Supplemental Text 1). Recruitment occurred in two stages, allowing 198 participants time to consider involvement. Initially, phone calls assessed interest, followed by 199 consent and eligibility determination. PRIMERO recruiters at the HIMA labor and delivery ward 200 used PRIMERO-DB to cross-reference consented participants. The second consent stage

Running Head: PRIMERO Birth Cohort

- 201 occurred after the child was born pre-discharge when mothers were allowed to reaffirm their
- 202 participation. Protocols and documents were approved by the UCSF Institutional Review Board
- 203 (IRB) and a National Institutes of Health-appointed Observational Study Monitoring Board
- 204 (OSMB), ensuring data safety, study progress, and confidentiality protocols.
- 205

206 Enrollment, Study Visits, and Procedures

Study visits and procedures are detailed in **Table 1**. Briefly, study participation consists of an
enrollment visit, annual visits for the first five years of life, and recurring RI visits during the
first two years of life.

- 210
- 211 <u>Enrollment</u>

212 Before birth, expectant mothers in the HIMA OB/GYN clinic expressing interest in the study 213 were assessed for eligibility and consented. Inclusion and exclusion criteria are provided in 214 **Table 2.** At birth, the newborns of consented mothers were assessed for eligibility, and cord 215 blood was collected. In the recovery ward of HIMA hospital, mothers of eligible infants were 216 approached with a reconsent. Reconsented mothers were then administered a baseline 217 questionnaire by trained staff who also collected peripheral blood from the mother and nasal 218 swabs of the inferior turbinates of the newborn. The cord blood collected from infants whose 219 mothers did not reconsent and those infants deemed not eligible was discarded, and infants were 220 not enrolled into the study. Blood and nasal samples were processed at CNP, the core facility for 221 our recruitment and follow-up procedures, located in the building adjacent to HIMA. After 222 processing, samples were shipped to each of the laboratory cores: blood to the UCSF Pediatric 223 Asthma Biobank and nasal swabs to the NJH Nasal Airway Biobank (Supplemental Text 2).

Running Head: PRIMERO Birth Cohort

224

225 <u>Annual Visits</u>

226 Initially, annual visits and questionnaires were aligned with the child's birthday. However, due to 227 the COVID-19 pandemic, the window was extended to 8 months post-birthday to accommodate 228 stay-at-home mandates and vaccination rollouts. For safety and efficiency, questionnaires are 229 conducted separately by trained PRIMERO staff via phone, utilizing the secure UCSF Research 230 Electronic Data Capture (REDCap) software (34,35). Questionnaires administered at newborn 231 and annual follow-up visits during the child's initial five years gather comprehensive data on 232 environmental factors, demographic variables, social aspects, and clinical risk factors associated 233 with recurrent wheezing and asthma. Biospecimens are collected annually during healthy 234 periods, and the mAPI is assessed at 2 years. Annual visits include recording anthropometrics, an 235 eczema assessment, and collection of two nasal swabs. In the second year, peripheral blood is 236 processed for allergen sensitization. In the third year, impulse oscillometry is conducted with the 237 plan for spirometry in subsequent years to evaluate lung function. Annual nasal swabs are sent to 238 the NJH Nasal Airway Biobank, and year two blood samples go to the UCSF Pediatric Asthma 239 Biobank after processing at CNP.

240

241 <u>Respiratory Illness Surveillance</u>

After discharge from the hospital following birth, participants enter the RI surveillance phase of the study (**Figure 2**), which lasts for the first two years of life. Mothers of participating infants receive a weekly automated SMS text or email that provides a hyperlink to indicate whether the child has signs of RI (**Supplemental Figure 1**). Text and email messages that are unanswered within 24 hours or have an affirmative response are compiled into a weekly call list, followed by

Running Head: PRIMERO Birth Cohort

247	a phone call from	n project staff	. In addition t	o active surv	veillance,	mothers can	call PRIMERO
-----	-------------------	-----------------	-----------------	---------------	------------	-------------	--------------

- staff or visit the clinic for a phone-based or face-to-face assessment. Illness assessments, visits,
- follow up, and severity determination are further described in **Supplemental Text 3**.
- 250

251 Biospecimen Collection

- 252 Cord and maternal blood are collected at enrollment to define genome-wide genetic variation in
- 253 mothers and children. Nasal swabs are collected from newborns at enrollment, at each annual
- visit, and during in-person RI visits. Illness swabs are tested for SARS-CoV-2 and enterovirus
- 255 D68 using PCR assays and for 22 other common respiratory pathogens using the NxTAG
- 256 Respiratory Pathogen Panel. Nasal swabs are also used to evaluate longitudinal airway gene
- 257 expression in health and illness using whole transcriptome RNA-sequencing. In addition, blood
- is collected at the year 2 visit to obtain complete blood counts with differentials and assess
- allergen sensitization via specific IgE testing to perennial aeroallergens and foods.
- 260

261 Respiratory Illness Outcomes

- 262 RI outcomes of the study include the following:
- 263 1. Identification of early-life RIs.
- 264 2. Analysis of RI-associated airway gene expression.
- 265 3. Determination of respiratory virus infection at a species level.
- 266 4. The modified asthma predictive index (mAPI).
- 267 Secondary RI outcomes and the secondary research questions we aim to address with these
- 268 outcomes are described in **Supplemental Text 4.**
- 269

Running Head: PRIMERO Birth Cohort

270 Identification of Children with Early-life LRIs

- 271 Participants will be classified at the end of their 2-year surveillance period based on the severity
- of LRI(s) experienced: did not experience an LRI; experienced at least one mild/moderate LRI,
- but not a severe LRI; or experienced at least one severe LRI. In most cases, LRIs in the first two
- 274 years of life are determined by a physician assessment. However, due to missed visits for some
- 275 participants, a subset of LRIs is only defined by the symptoms reported during the screening and
- tracking of an illness event.
- 277

278 Analysis of Respiratory Illness-Associated Airway Gene Expression

279 We will use RNA sequencing to measure whole transcriptome nasal airway epithelium gene

280 expression patterns at birth, during defined URI and LRI events, and from annual follow-up

visits from ages one through five.

282

283 Determination of Respiratory Virus Infection at a Species Level

Viral species-specific data generated from nasal airway swab RNA and metagenomic analysis of

285 RNA-sequence data will allow us to determine if a participant has been infected with a

respiratory virus and determine if viral species are associated with illness severity outcomes.

- 287
- 288 <u>mAPI</u>

289 Children undergo clinical assessment for asthma risk at two years of age via the mAPI, which is

an updated iteration of the asthma predictive index (API) and provides an assessment for future

asthma risk (36). The mAPI has greater sensitivity than the API and has been included in the

292 National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 (EPR-3)

Running Head: PRIMERO Birth Cohort

293	guidelines as a criterion for the institution of long-term therapy to decrease asthma morbidity and
294	exacerbations (37).

295

296 Risk Mitigation Plan

- 297 Study enrollment commenced in March 2020, coinciding with the onset of the COVID-19
- 298 pandemic. After considering the risks of pandemic viral exposures to staff and participants,
- 299 PRIMERO leadership, in conjunction with HIMA, NHLBI, and the OSMB, decided to proceed
- 300 with the study, operating under a risk mitigation plan (**Supplemental Text 5**).
- 301

302 Participant Engagement

- 303 To enhance retention and engagement, mothers are initially reimbursed for parking costs at
- 304 HIMA during recruitment, and they receive a thank-you gift at the conclusion of the baseline and
- 305 each annual follow-up visit. Beyond study visits, participants are regularly contacted through
- 306 various channels, including SMS texts, email, and the study website (Supplemental Figure 2).
- 307 The study website and newsletters serve to keep participants informed about the study's progress
- 308 and provide prompts for updating contact information. Weekly contacts during the first two years
- help identify RIs, and personalized SMS texts with a link to the study website are sent on the
- 310 child participants' birthdays. Additionally, participants receive annual holiday greetings via
- 311 email.

312

313 **RESULTS**

314 Recruitment

Running Head: PRIMERO Birth Cohort

315	Enrollment began in late February 2020 with the first eligible infant born in early March,
316	coinciding with the first reported cases of COVID-19 in Puerto Rico, at which point the governor
317	of Puerto Rico ordered an island-wide curfew and closure of non-essential businesses in mid-
318	March 2020 (38). As additional pandemic control measures ensued, PRIMERO remained one of
319	few studies that was successfully able to actively recruit through the height of the pandemic and
320	continued enrolling until June 2023. Over the 40-month recruitment period, HIMA delivered
321	3,543 babies. Mothers who delivered over the weekends or received prenatal care outside of
322	HIMA were not considered for recruitment. We approached 2,723 of those mothers with
323	welcome packets and screened them for potential enrollment. Of those, 318 mothers declined
324	participation, 183 mothers were ineligible, 12 did not reaffirm their consent, one birth was
325	missed, and 109 infants were not eligible, culminating in a total of 2,100 mother-child dyads
326	being enrolled in the study (Figure 3) representing 59% of all of HIMA births.
327	
328	Descriptive Characteristics of Participants

Characteristics of PRIMERO mothers and children (**Table 3**) were derived from a baseline questionnaire and infant eligibility form. The median age of mothers was 26.6 (IQR, 23.1–30.7) years. Cesarean delivery was the predominant (72.6%) delivery method, with most (53.9%) unplanned. The race of each child was derived from the parents' reported races, with 39.0% White if both parents identified as White, 22.0% Black/African if both parents identified as Black/African, and 39.0% Other/Mixed if one parent identified as White and the other as Black/African, encompassing all possible combinations (39).

336

337 Annual Visits and Biospecimen Collection

338	Among children eligible for annual visits, 57% of expected visits occurred and 62% of expected
339	questionnaires were completed as of February 3, 2024. Nasal swabs were successfully collected
340	from 99% of these children, and blood samples were obtained from 97%. Among children three
341	years and older who attended their third annual visit, 54% have completed impulse oscillometry.
342	
343	Participant Retention
344	As of February 3, 2024, 1,940 study participants remain actively engaged, while 136 are on
345	standby status whereby the participant requested reduced contact frequency, relocated from
346	Puerto Rico, or informed us of an inability to commit to future follow-up. Additionally, 23
347	participants withdrew from the study and one child died due to reasons unrelated to the study.
348	
349	Adverse Events
350	Related adverse events are defined as any unfavorable medical occurrence attributed to a
351	PRIMERO procedure, such as blood draw, nasal swab, or pulmonary function testing. A singular
352	adverse event was recorded, involving a syncopal episode during a child's blood draw.
353	
354	DISCUSSION
355	The Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes
356	(PRIMERO) was designed to unravel the early life social, environmental, and genetic
357	contributors to severe respiratory wheezing and subsequent asthma. A primary goal is to
358	characterize the relationship between viral RIs in early life and the subsequent development of
359	childhood asthma, focusing on the pivotal role of airway epithelial dysfunction. PRIMERO sets
360	out to determine whether this dysfunction manifests at birth or emerges as a consequence of viral

Running Head: PRIMERO Birth Cohort

361	RIs during infancy and early childhood. Our prospective birth cohort study is poised to yield
362	groundbreaking insights into the genetic and viral risk factors associated with severe RIs.
363	Furthermore, it aims to pinpoint distinct airway cellular developmental trajectories observable in
364	children at high risk for asthma, both at birth, following RIs, and during periods free of
365	respiratory symptoms preceding the onset of asthma.
366	
367	"Primero" means "first" in Spanish, signifying PRIMERO as the inaugural asthma birth cohort
368	study in Puerto Rico. The imperative for comprehensive research across diverse genomes cannot
369	be overstated as it is fundamental to advancing science and medicine (40,41). Despite significant
370	attention and resources directed toward genetic research, globally diverse populations remain
371	notably underrepresented (42). Here, PRIMERO is helping to bridge this gap towards equal
372	representation of study populations in biomedical science. The emphasis of PRIMERO on the
373	population of Puerto Rico is emblematic of the Strategic Vision of NHLBI, which underscores
374	the exploration of factors contributing to health disparities among diverse populations (43).
375	Additionally, recruitment and follow-up activities are exclusively conducted within Puerto Rico,
376	in close partnership with local investigators, clinicians, and other Puerto Rican professionals,
377	enriching the biomedical workforce with diversity and expertise.
270	

378

A fundamental strength of PRIMERO lies in its innovative approach, capitalizing on the minimally invasive nature of nasal airway swabs to procure critical respiratory samples at multiple times: at birth, during early-life RIs, and annually for the first five years of life (30,44,45). Our study utilizes cutting-edge multiplexed molecular assays, enabling the identification of a spectrum of RI-causing viruses, including RSV, HRV, metapneumovirus,

Running Head: PRIMERO Birth Cohort

384	coronaviruses, parainfluenza, influenza, and other less studied species. Collected specimens from
385	PRIMERO participants undergo genetic characterization, allowing us to determine the role of
386	genetic variation in the effects of these viruses on LRI and asthma. Most notably, through
387	transcriptomic analyses of nasal airway mucosa, the PRIMERO study introduces a
388	groundbreaking approach by longitudinally characterizing molecular airway dysfunction at birth,
389	annually throughout childhood, and during RIs in the first two years of life. Extensive research
390	substantiates the effectiveness and reliability of nasal swabbing, underscoring critical findings: it
391	reveals that the upper and lower airways share similar cell types and expression patterns, and
392	upper airway insults can elicit lower airway symptoms and immune responses (30,46–49). The
393	inflammatory endotypes of asthma observed in both the nasal and bronchial airways exhibit a
394	high degree of correlation, emphasizing the importance of the nasal airway epithelium as a
395	primary site for infection with asthma-associated respiratory viruses (30). Furthermore, we
396	previously demonstrated the versatility of RNA-sequence data generated from nasal airway
397	epithelial swabs, serving a dual purpose: elucidating host transcriptional profiles and screening
398	samples for pathogenic respiratory viruses through metagenomic analysis (50). This single-swab
399	RNA-sequence approach offers a robust and tightly controlled assessment of the host response to
400	viral infection and stands as a central analysis method within our study.

401

As with any complex study, PRIMERO has its unique challenges. One challenge was the low
birth rate in Puerto Rico, which, at 0.90 births per woman, is approximately half that in the
mainland U.S. (51). Despite the relatively small source population of potential participants,
PRIMERO recruitment has been overwhelmingly successful. Another challenge was the lack of
available software to manage the recruitment, surveillance, and follow-up of 2,100 mother-child

Running Head: PRIMERO Birth Cohort

407	dyads and to interact with their electronic medical record (EMR) as they progress through the
408	study. A key innovation was the creation of PRIMERO-DB to address this need. PRIMERO-DB
409	has the same Health Insurance Portability and Accountability Act (HIPAA) securities as EMR
410	data and is available from any web-enabled device, providing user-specific permissions to
411	authorized users. Additionally, the COVID-19 pandemic coincided with the start of PRIMERO
412	recruitment. With pandemic control measures in place and OB/GYN offices limiting their indoor
413	capacity, recruiters lost the advantage of building the rapport provided through face-to-face
414	interactions. As recruitment continued throughout the evolving pandemic, the generalizability of
415	our findings to babies born before and after the pandemic will need to be evaluated.
416	
416 417	Creating a birth cohort uniquely positions us to answer questions about the early-life origins of
	Creating a birth cohort uniquely positions us to answer questions about the early-life origins of health and disease. We aim to leverage this rare opportunity to study the broader health of
417	
417 418	health and disease. We aim to leverage this rare opportunity to study the broader health of
417 418 419	health and disease. We aim to leverage this rare opportunity to study the broader health of children over the next decades. Given adequate support, long-term prospective follow-up of
417 418 419 420	health and disease. We aim to leverage this rare opportunity to study the broader health of children over the next decades. Given adequate support, long-term prospective follow-up of PRIMERO participants will enable studies of numerous exposures and outcomes and enable the
417 418 419 420 421	health and disease. We aim to leverage this rare opportunity to study the broader health of children over the next decades. Given adequate support, long-term prospective follow-up of PRIMERO participants will enable studies of numerous exposures and outcomes and enable the identification of biomarkers that may predict outcomes well before their traditional diagnosis.
417 418 419 420 421 422	health and disease. We aim to leverage this rare opportunity to study the broader health of children over the next decades. Given adequate support, long-term prospective follow-up of PRIMERO participants will enable studies of numerous exposures and outcomes and enable the identification of biomarkers that may predict outcomes well before their traditional diagnosis. This information collectively promises insights into potential pathways that may be targetable in

426 ACKNOWLEDGMENTS

The authors acknowledge the families for their participation and thank the numerous data
collectors, recruiters, technicians, and hospital administrators for their support and participation
in PRIMERO. The authors would also like to thank Iliany Cubero, Peter Deford, George Halley,

- 430 Michael Montgomery, James Nolin, Bhavika Patel, Elizabeth Plender, Lisa Butler, and Narjis
- 431 Kazmi. We also extend a special thank you to the San Francisco Chinatown Merchants
- 432 Association for their generous donations of personal protective equipment during the COVID-19
- 433 pandemic.
- 434
- 435 Abbreviations
- 436 API asthma predictive index
- 437 CNP Centro de Neumología Pediátrica
- 438 COVID-19 coronavirus disease 2019
- 439 EMR electronic medical record
- 440 EPR-3 Expert Panel Report 3
- 441 GxE gene-environment
- 442 HIMA Hospital Interamericano de Medicina Avanzada
- 443 HIPAA Health Insurance Portability and Accountability Act
- 444 HRV human rhinovirus
- 445 IIAQ Initial Illness Assessment Questionnaire
- 446 IRB Institutional Review Board
- 447 ITFQ Illness Tracking and Follow-up Questionnaire
- 448 LRI lower respiratory tract illnesses
- 449 mAPI modified asthma predictive index
- 450 MDIQ Medical Doctor Illness Questionnaire
- 451 NAEPP National Asthma Education and Prevention Program
- 452 NIH National Institutes of Health

Running Head: PRIMERO Birth Cohort

453	NJH	National Jewish Health

- 454 non-RI non-respiratory tract illness
- 455 OB/GYN obstetric/gynecologic
- 456 OSMB Observational Study Monitoring Board
- 457 PRAM Pediatric Respiratory Assessment Measure
- 458 PRIMERO Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory
- 459 Outcomes
- 460 qPCR quantitative polymerase chain reaction
- 461 REDCap Research Electronic Data Capture
- 462 RI respiratory illness
- 463 RNA ribonucleic acid
- 464 RSS Respiratory Severity Score
- 465 RSV respiratory syncytial virus
- 466 SMS short message service
- 467 UCSF University of California, San Francisco
- 468 URI upper respiratory tract illness
- 469

470 **REFERENCES**

- Johnson CC, Havstad SL, Ownby DR, et al. Pediatric asthma incidence rates in the United
 States from 1980 to 2017. *J Allergy Clin Immunol*. 2021;148(5):1270–1280.
- 473 2. Table 4-1- Current Asthma Prevalence Percents by Age, United States: NHIS, 2018 | CDC.
 474 2019;(https://www.cdc.gov/asthma/nhis/2018/table4-1.htm). (Accessed January 8, 2024)
- 475 3. Lugogo N, Judson E, Haight E, et al. Severe asthma exacerbation rates are increased among female, Black, Hispanic, and younger adult patients: results from the US
 477 CHRONICLE study. *J Asthma*. 2022;59(12):2495–2508.

- 4. Miller RL, Schuh H, Chandran A, et al. Incidence rates of childhood asthma with recurrent
 exacerbations in the US Environmental influences on Child Health Outcomes (ECHO)
 program. *J Allergy Clin Immunol*. 2023;152(1):84–93.
- 481 5. Keet CA, Matsui EC, McCormack MC, et al. Urban residence, neighborhood poverty,
 482 race/ethnicity, and asthma morbidity among children on Medicaid. *J Allergy Clin Immunol*.
 483 2017;140(3):822–827.
- 484 6. Washington DM, Curtis LM, Waite K, et al. Sociodemographic Factors Mediate Race and
 485 Ethnicity-associated Childhood Asthma Health Disparities: a Longitudinal Analysis. J
 486 Racial Ethn Health Disparities. 2018;5(5):928–938.
- 487 7. Wohlford EM, Borrell LN, Elhawary JR, et al. Differential asthma odds following
 488 respiratory infection in children from three minority populations. *PLoS One*.
 489 2020;15(5):e0231782.
- 490 8. den Dekker HT, Jaddoe VWV, Reiss IK, et al. Fetal and Infant Growth Patterns and Risk of
 491 Lower Lung Function and Asthma. The Generation R Study. *Am J Respir Crit Care Med*.
 492 2018;197(2):183–192.
- 9. Örtqvist AK, Ullemar V, Lundholm C, et al. Fetal Growth and Childhood Lung Function in
 the Swedish Twin Study on Prediction and Prevention of Asthma. *Ann Am Thorac Soc*.
 2017;14(7):1147–1153.
- 496 10. Martinez FD, Guerra S. Early Origins of Asthma. Role of Microbial Dysbiosis and
 497 Metabolic Dysfunction. *Am J Respir Crit Care Med*. 2018;197(5):573–579.
- 498 11. Bouzigon E, Corda E, Aschard H, et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. *N Engl J Med.* 2008;359(19):1985–1994.
- Taussig LM, Wright AL, Holberg CJ, et al. Tucson Children's Respiratory Study: 1980 to
 present. *J Allergy Clin Immunol*. 2003;111(4):661–675; quiz 676.
- McGuiness CB, Boron ML, Saunders B, et al. Respiratory syncytial virus surveillance in
 the United States, 2007-2012: results from a national surveillance system. *Pediatr Infect Dis J.* 2014;33(6):589–594.
- Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life
 predict asthma development in high-risk children. *Am J Respir Crit Care Med*.
 2008;178(7):667–672.
- 508 15. Kusel MMH, de Klerk NH, Kebadze T, et al. Early-life respiratory viral infections, atopic
 509 sensitization, and risk of subsequent development of persistent asthma. *J Allergy Clin*510 *Immunol.* 2007;119(5):1105–1110.
- 511 16. Molinari Such M, García I, García L, et al. Respiratory syncytial virus-related bronchiolitis
 512 in Puerto Rico. *P R Health Sci J*. 2005;24(2):137–140.

- 513 17. Castro-Rodriguez JA, Forno E, Rodriguez-Martinez CE, et al. Risk and Protective Factors
 514 for Childhood Asthma: What Is the Evidence? *J Allergy Clin Immunol Pract*.
 515 2016;4(6):1111–1122.
- 516 18. Castro-Rodríguez JA, Holberg CJ, Wright AL, et al. A clinical index to define risk of
 517 asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med*. 2000;162(4
 518 Pt 1):1403–1406.
- 19. Rosas-Salazar C, Chirkova T, Gebretsadik T, et al. Respiratory syncytial virus infection
 during infancy and asthma during childhood in the USA (INSPIRE): a population-based,
 prospective birth cohort study. *Lancet*. 2023;401(10389):1669–1680.
- 522 20. Calışkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheezing illness and genetic
 523 risk of childhood-onset asthma. *N Engl J Med*. 2013;368(15):1398–1407.
- Rosas-Salazar C, Tang Z-Z, Shilts MH, et al. Upper respiratory tract bacterial-immune
 interactions during respiratory syncytial virus infection in infancy. *J Allergy Clin Immunol*.
 2022;149(3):966–976.
- 527 22. Chirkova T, Rosas-Salazar C, Gebretsadik T, et al. Effect of Infant RSV Infection on
 528 Memory T Cell Responses at Age 2-3 Years. *Front Immunol*. 2022;13:826666.
- 529 23. Connelly AR, Jeong BM, Coden ME, et al. Metabolic Reprogramming of Nasal Airway
 530 Epithelial Cells Following Infant Respiratory Syncytial Virus Infection. *Viruses*.
 531 2021;13(10).
- 532 24. Human S, Hotard AL, Rostad CA, et al. A Respiratory Syncytial Virus Attachment Gene
 533 Variant Associated with More Severe Disease in Infants Decreases Fusion Protein
 534 Expression, Which May Facilitate Immune Evasion. *J Virol.* 2020;95(2).
- S35 25. Rosas-Salazar C, Shilts MH, Tovchigrechko A, et al. Nasopharyngeal Microbiome in
 Respiratory Syncytial Virus Resembles Profile Associated with Increased Childhood
 Asthma Risk. *Am J Respir Crit Care Med.* 2016;193(10):1180–1183.
- 538 26. Brunwasser SM, Snyder BM, Driscoll AJ, et al. Assessing the strength of evidence for a
 539 causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent
 540 wheezing illness: a systematic review and meta-analysis. *Lancet Respir Med.*541 2020;8(8):795–806.
- 542 27. Fang L-C, Wang J-Y, Yu H-H, et al. Respiratory-syncytial virus immunoprophylaxis on
 543 asthma symptoms development in prematurity with bronchopulmonary dysplasia. *J Allergy*544 *Clin Immunol Glob*. 2023;2(4):100161.
- 545 28. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to
 546 Prevent RSV Illness in Infants. *N Engl J Med.* 2023;388(16):1451–1464.
- 547 29. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late548 Preterm and Term Infants. *N Engl J Med.* 2022;386(9):837–846.

549 550	30.	Poole A, Urbanek C, Eng C, et al. Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. <i>J Allergy Clin Immunol</i> . 2014;133(3):670-678.e12.
551 552 553	31.	Burchard EG, Avila PC, Nazario S, et al. Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. <i>Am J Respir Crit Care Med.</i> 2004;169(3):386–392.
554 555 556	32.	Nishimura KK, Galanter JM, Roth LA, et al. Early-life air pollution and asthma risk in minority children. The GALA II and SAGE II studies. <i>Am J Respir Crit Care Med</i> . 2013;188(3):309–318.
557 558 559	33.	U.S. Census Bureau. San Juan-Carolina-Caguas, PR Metro Area. (https://censusreporter.org/profiles/31000US41980-san-juan-carolina-caguas-pr-metro- area/)
560 561 562	34.	Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)a metadata-driven methodology and workflow process for providing translational research informatics support. <i>J Biomed Inform</i> . 2009;42(2):377–381.
563 564	35.	Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. <i>J Biomed Inform</i> . 2019;95:103208.
565 566	36.	Chang TS, Lemanske RFJ, Guilbert TW, et al. Evaluation of the modified asthma predictive index in high-risk preschool children. <i>J Allergy Clin Immunol Pract</i> . 2013;1(2):152–156.
567 568	37.	Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma- Summary Report 2007. <i>J Allergy Clin Immunol</i> . 2007;120(5 Suppl):S94-138.
569 570 571 572 573	38.	Puerto Rico COVID Resources Government Actions: COVID-19 Coronavirus COVID 19 Resource Center Topics Insights Faegre Drinker Biddle & Reath LLP. (https://www.faegredrinker.com/en/insights/topics/coronavirus-covid-19-resource- center/government-actions-covid-19/puerto-rico-covid-resources). (Accessed September 19, 2023)
574 575 576	39.	Puerto Rico's 2020 Race/Ethnicity Decennial Analysis CentroPR. (https://centropr.hunter.cuny.edu/reports/puerto-ricos-2020-decennial-analysis-datasheet- series/). (Accessed January 8, 2024)
577 578	40.	Oh SS, Galanter J, Thakur N, et al. Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled. <i>PLoS Med.</i> 2015;12(12):e1001918.
579 580	41.	Choudhury A, Aron S, Botigué LR, et al. High-depth African genomes inform human migration and health. <i>Nature</i> . 2020;586(7831):741–748.
581 582	42.	Mills MC, Rahal C. A scientometric review of genome-wide association studies. <i>Commun Biol.</i> 2019;2:9.

Running Head: PRIMERO Birth Cohort

- 43. Research Priorities | NHLBI, NIH. (https://www.nhlbi.nih.gov/about/strategic-vision/research-priorities). (Accessed September 19, 2023)
- 585 44. Sajuthi SP, DeFord P, Li Y, et al. Type 2 and interferon inflammation regulate SARS-CoV2 entry factor expression in the airway epithelium. *Nat Commun.* 2020;11(1):5139.
- 587 45. Chu C-Y, Qiu X, Wang L, et al. The Healthy Infant Nasal Transcriptome: A Benchmark
 588 Study. *Sci Rep.* 2016;6:33994.
- 46. Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. *Toxicol Pathol*.
 2006;34(3):252–269.
- 592 47. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal
 593 provocation with allergen. *J Allergy Clin Immunol*. 1992;89(2):611–618.
- 48. Littell NT, Carlisle CC, Millman RP, et al. Changes in airway resistance following nasal provocation. *Am Rev Respir Dis*. 1990;141(3):580–583.
- 596 49. Schumacher MJ, Cota KA, Taussig LM. Pulmonary response to nasal-challenge testing of
 597 atopic subjects with stable asthma. *J Allergy Clin Immunol*. 1986;78(1 Pt 1):30–35.
- 598 50. Wesolowska-Andersen A, Everman JL, Davidson R, et al. Dual RNA-seq reveals viral infections in asthmatic children without respiratory illness which are associated with changes in the airway transcriptome. *Genome Biol.* 2017;18(1):12.
- 601 51. World Bank Open Data. World Bank Open Data. (https://data.worldbank.org). (Accessed
 602 January 8, 2024)

603

Running Head: PRIMERO Birth Cohort

Visit	Prenatal	Birth	Age 1	Age 2	Age 3	Age 4	Age
Recruitment		1					
• Eligibility and informed consent	Х	Х					
Baseline questionnaire		Х					
Cord blood		Х					
Maternal blood		Х					
Nasal swabs		Χ					
Annual follow-up visits							
Annual questionnaire			Х	X	X	X	X
Anthropometrics			Х	X	Х	Х	X
Nasal swabs			Х	X	Х	X	X
Blood draw				Χ			
Impulse oscillometry					Х		
• Spirometry						Х	
Respiratory illness surveillance (recurring)							
• Weekly SMS text/ or email messaging			Х				
• In-person clinical illness assessments		X					
 Respiratory illness questionnaire 			Х				
 URI Nasal swabs 		1 st URI per year					
 LRI Nasal swabs 		All	LRI ev	vents			

604 **Table 1.** Schedule of study procedures and visits

Abbreviations: LRI, lower respiratory tract illness; SMS, short message service; URI, upper

606 respiratory tract illness.

Running Head: PRIMERO Birth Cohort

607	Table 2. P	RIMERO Enrollment Inclusion and Exclus	sion
		Inclusion	Exclusion
	Mother	Residential address in Puerto Rico	
		At least 18 years of age	
		Have SMS text-enabled phone or	
		working email address	
		Able to read and understand English or	
		Spanish	
		Delivery at HIMA	
	Newborn	Lives with biological mother	Sibling of a child already enrolled in
			PRIMERO
		At least 37 ^a weeks gestational age	Multiple birth ^c
		Birthweight of at least 2,500 g ^b	Requires mechanical ventilation
		Afebrile (<38°C)	Immune compromised
		No clinical signs of respiratory infection	Congenital ^d or neuromuscular ^e disorders
608		ons: SMS, short message service; HIMA, H	Hospital Interamericano de Medicina
609	Avanzada-	San Pablo; g, grams; C, Celsius	
610	0		
611		s at least 36 weeks gestational age and ^b we	
612	· · ·	6	for inclusion on a case-by-case basis by an
613		n/pediatrician who determined by physical	examination that the child was otherwise
614	healthy.		
615	601		11
616	^e Only one	child of a multiple birth is allowed to enro	11.
617	d F	in the design of the second life of the second life of the second s	
618	Example	s include pulmonary abnormalities and Dov	wn syndrome.

607 **Table 2.** PRIMERO Enrollment Inclusion and Exclusion

^e Impaired ability to clear airway secretions.

Running Head: PRIMERO Birth Cohort

621 Table 3. Characteristics of Enrolled Mothers and Children in PRIMERO, Puerto Rico, as of

622 February 3, 2024	
----------------------	--

Characteristic	No. of Participants	%	Median (IQR)
Maternal age, years			26.6 (23.1 - 30.7)
Cesarean deliveries	1,524	72.6	
Unplanned Cesarean	821	39.1	
Gestational age, weeks			38.7 (38.0 - 39.4)
Birth weight, grams			3,202 (2,915 - 3,466)
Child's sex, male	1,047	49.8	
Child's race ^a			
Black/African	461	22.0	
Other/Mixed	818	39.0	
White	820	39.0	
Not specified	1	0.0	
Perinatal antibiotics exposure ^b	433	20.7	
Maternal prenatal smoking ^c	22	1.1	
Maternal education status, low ^d	739	35.2	
Paternal education status, low ^d	946	45.1	

623

624 Abbreviations: IQR, interquartile range

625

^a Child's race as a derivation of parents' reported races: "White" if both parents identified as

White, "Black/African" if both parents identified as Black/African, and "Other/Mixed" if one
parent identified as White and the other as Black/African.

629

^b Perinatal antibiotic exposure if neonate was administered antibiotics in 3rd trimester or neonate
 was administered antibiotics soon after birth.

632

^c Maternal prenatal smoking if mother reported smoking during pregnancy or reported time from
 quitting is less than child's gestation age.

635

636 ^d Low educational status if reported highest level of education as "Less than high school

637 education" or "High school education or GED.

Running Head: PRIMERO Birth Cohort

638 **Figure 1.** Municipalities and population density of Puerto Rico






640

- 641 Redder areas represent municipalities with higher population densities. Greener areas represent
- 642 lower population densities. The San Juan-Baymón-Carolina metropolitan area, bordered in blue,
- 643 represents HIMA's catchment area.

Running Head: PRIMERO Birth Cohort

644 **Figure 2.** Illness Surveillance Flow Diagram



645

646 Abbreviations: IIAQ, Initial Illness Assessment Questionnaire; ITFQ, Illness Tracking and


Follow-up Questionnaire; LRI, lower respiratory tract illnesses; MDIQ, Medical Doctor Illness
 Questionnaire; non-RI, non-respiratory tract illness; SMS, short message service; URI, upper

respiratory tract illness. Participants move through statuses assigned at each node to track the

650 illness from onset until resolution.

Running Head: PRIMERO Birth Cohort

Figure 3. Flowchart of PRIMERO enrollment spanning February 2020 to June 2023.



652